July 23, 2025

Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R- CHP) therapy in diffuse large B-cell lymphoma in patients aged 80 years or older: A real- world study

View Full Paper

Ask AI

Bookmark

Authors

TYToshiki YamadaGifu Prefectural General Medical Center NNNobuhiko NakamuraGifu University Hospital HGHideko GotoNational Institute of Technology, Gifu College

Discussion

Member takes

Implication

Multicenter retrospective cohort study reports a high response rate in older adults with DLBCL using Pola-R-CHP, highlighting treatment-related mortality concerns.

Key Points

The overall response rate for DLBCL patients aged ≥ 80 years was 89.5%, slightly lower than 97.3% for those aged < 80 years.
Treatment-related mortality was notably higher in older patients at 11.4%, compared to 2.3% in younger counterparts.
Median dose intensity for doxorubicin and cyclophosphamide was significantly lower in the older cohort, while polatuzumab dosing remained steady.
Individualized dose adjustments and nutritional assessments are crucial for enhancing treatment outcomes and managing toxicity in elderly patients.

Cite This Study

Yamada et al. (2025) studied this question.

synapsesocial.com/papers/689a061be6551bb0af8cdb09 https://doi.org/10.21203/rs.3.rs-7112709/v1

View Full Paper

Ask AI

Bookmark

Implication

Multicenter retrospective cohort study reports a high response rate in older adults with DLBCL using Pola-R-CHP, highlighting treatment-related mortality concerns.

Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R- CHP) therapy in diffuse large B-cell lymphoma in patients aged 80 years or older: A real- world study

Discussion

Member takes

Implication

Key Points

Cite This Study

Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R- CHP) therapy in diffuse large B-cell lymphoma in patients aged 80 years or older: A real- world study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider